Gribbles Now Renamed to Innoquest

The independent diagnostic laboratory services provider, today announced its rebrand to Innoquest, as well as expanded offerings.

Its expansion of offerings include the latest and most comprehensive testing capabilities, a state-of-the-art IT support system and a larger global network of medical expertise. With this, its Malaysian entities are now aligned with the global brand of Innoquest, all under the Pathology Asia Holdings Group of clinical labs – the fastest-growing in-vitro diagnostic test provider with a strong presence in Singapore, Malaysia, Vietnam, Philippines, Australia and Indonesia.

The Innoquest brand in Malaysia will be held under the Innoquest Pathology Sdn Bhd.

Innoquest Pathology is the ONLY multidisciplinary clinical laboratory in Malaysia to hold both College of American Pathology (CAP) and MS ISO15189 accreditations, reinforcing its best-in-class standards, services, and laboratory practices. Moving forward, this gives the diagnostics hub greater opportunities to strengthen its global presence as a centre of excellence in testing. 

The rebrand to Innoquest introduces an enhanced IT infrastructure that integrates all lab-related activities to provide a seamless experience for medical professionals and patients. BioMark, a proprietary end-to-end platform, will connect Innoquest’s laboratories with healthcare providers, patients and third-party stakeholders to provide digitalised ordering
and processing of tests, real-time access to test results and remote patient monitoring via comprehensive electronic records. 

“The decision to rebrand to Innoquest is an important one, and showcases our continued commitment to fast, reliable, accessible and best-in-class services,” said Dr Nelson Nheu, Chief Executive Officer of Innoquest Pathology.

“The last two years have demonstrated a need for robust response to new developments in the global health landscape. Being a part of this strong regional network ensures that Innoquest Pathology is equipped with novel technologies, wider expertise in clinical laboratory practices and the capability to respond quickly and effectively, to improve its overall service delivery as a leading global diagnostics hub,” he added.

Previous articleTNB’s 1QFY22: Group’s PAT Down Double Digit by 10.5% Due To Increase In Fuel Price
Next articleTowerCos Will Drive Economic Growth Across Emerging Markets: Study By Edotco and Roland Berger


Please enter your comment!
Please enter your name here